MRI in Differential Diagnosis



Similar documents
Multiple Sclerosis: An imaging review and update on new treatments.

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

Neurosarcoidosis. Jeffrey M. Gelfand, MD

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

Using the MS Clinical Course Descriptions in Clinical Practice

CNS DEMYLINATING DISORDERS

MULTIPLE SCLEROSIS Update. Disclosures. Multiple Sclerosis. I do not have any disclosures. E. Torage Shivapour, M.D.

Life with MS: Striving for Maximal Independence & Fulfillment

Multiple Sclerosis Jeffrey M. Gelfand, MD

2.1 Who first described NMO?

Guidance for evaluation of new neurological symptoms in patients receiving TYSABRI

Natalizumab and the Risk of PML

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

MS ECHO: Update on MS treatment. Gary Stobbe, MD Medical Director, MS Project ECHO Clinical Assistant Professor, UW Neurology

Transverse Myelitis ISBN A guide for patients and carers

Multiple Sclerosis. Matt Hulvey BL A - 615

CBT IN THE CITY. adjusted to the news of being with MS? April Experts at your fingertips call now. Check out our new services in you local area

FastTest. You ve read the book now test yourself

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

New Treatment Options for MS Patients: Understanding risks versus benefits

Homework 5: Differential Diagnosis of Multiple Sclerosis

A Rare Image. Dean M. Cestari, MD Fred Jakobiec, MD Fred Hochberg, MD Joseph F. Rizzo III, MD Rebecca C. Stacy, MD PhD

Advances in the Use of MRI in the Management of MS. The Role of MRI in MS Management. Jack H. Simon Portland, Oregon

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

How To Get Ivig To Treat Neuromyelitis Optica

Understanding. Multiple Sclerosis. Tim, diagnosed in 2004.

Clinically isolated syndrome (CIS)

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Clinical Trials of Disease Modifying Treatments

Neuroimaging Christopher Bever, MD, MBA (MODERATOR) Use of MRI in Diagnosing and Monitoring MS Jack H. Simon, Portland, OR

AUBAGIO (teriflunomide) oral tablet

Progress in MS: Current and Emerging Therapies

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

III./5.3.: Multiple sclerosis. Epidemiology. Etiology. Pathology

Update: MRI in Multiple sclerosis

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

A Definition of Multiple Sclerosis

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

AUBMC Multiple Sclerosis Center

Lupus in Children and Teenagers. Arielle Hay, MD Pediatric Rheumatologist Nicklaus Children s Hospital

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

MULTIPLE SCLEROSIS Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

What is Multiple Sclerosis? Gener al information

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Multifocal Motor Neuropathy. Jonathan Katz, MD Richard Lewis, MD

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com

Best practices for using MS disease modifying therapies

MULTIPLE SCLEROSIS. Mary Beth Rensberger, RN, BSN, MPH Author

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF MULTIPLE SCLEROSIS

Acute demyelinating optic neuritis Rod Foroozan, MD, Lawrence M. Buono, MD, Peter J. Savino, MD, and Robert C. Sergott, MD

Management of spinal cord compression

Clinical features. Chapter 2. Clinical manifestations. Course

MSTAC Initial Application

Multiple Sclerosis (Dr. Merchut) 1. Pathophysiology

Advanced Multiple Sclerosis: Progressive MS Epidemiology

Return to same game if sx s resolve within 15 minutes. Return to next game if sx s resolve within one week Return to Competition

A neurologist would assess your eligibility and suitability for the DMTs.

Ms. Jackson is the Manager of Health Finance and Reimbursement, Division of Health Policy and Practice Services, Washington, DC.

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter

MULTIMODAL THERAPY FOR MS- ASSOCIATED COGNITIVE DYSFUNCTION

Understanding your Tecfidera treatment

Understanding your Tecfidera treatment

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

Original Policy Date

2 Differential Diagnosis

St. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor?

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

Whiplash injuries can be visible by functional magnetic resonance imaging. Pain Research and Management Autumn 2006; Vol. 11, No. 3, pp.

387

Treatment Optimization in MS: When to Start, When to Shift, when to Stop

IF YOU ARE RECEIVING TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS (NATALIZUMAB)

Global Multiple Sclerosis Market: Trends and Opportunities ( )

PLEX: For whom and how? Current and potential uses for MS and NMO

Disease Modifying Therapies for MS

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Trauma Insurance Claims Seminar Invitation

Treating Bulging Discs & Sciatica. Alexander Ching, MD

There's no cure for multiple sclerosis. However treatments can help treat attacks, modify the course of the disease and treat symptoms.

Transcription:

MRI in Differential Diagnosis Jill Conway, MD, MA, MSCE Director, Carolinas MS Center Clerkship Director, UNCSOM-Charlotte Campus Charlotte, NC DISCLOSURES Speaking, consulting, and/or advisory boards for Genzyme, Novartis, Bayer, and Teva. Institutional research support from Avanir, Biogen, Novartis, Roche, Teva. 1

OUTLINE Introduction to MRI T1/T2/FLAIR/gado what does it mean? Typical MRI findings in MS Differential diagnosis of MS on MRI Case studies Common and uncommon MS mimics MS spectrum on MRI MRI: TYPES OF IMAGING T1: good for brain anatomy T2: highlights pathology Fluid Attenuated Inversion Recovery (FLAIR): suppresses CSF signal T1 + gado: shows BBB breakdown 2

MRI: T1 IMAGING TYPICAL MS: T1 BLACK HOLES 3

MRI: T2 IMAGING Typical MS: Axial FLAIR 4

TYPICAL MS: SAGITTAL FLAIR SPINAL CORD MRI 5

MRI IN DIAGNOSIS: Periventricular, ovoid lesions Cerebellum frequently involved Corpus callosum lesions common Cortical lesions poorly seen on MRI MRI is highly variable MRI IN MS DIAGNOSIS Polman, et al. Ann Neurol. 2011 Feb;69(2):292-302. 6

DIFFERENTIAL DIAGNOSIS OF MS MS forms and mimics Neuromyelitis optica ADEM Balo s concentric sclerosis Marburg variant Genetic Adrenoleukodystrophy Leber s optic atrophy Mitochondrial diseases CADASIL Infectious HIV and HTLV Herpes viruses VZV JC virus Measles virus Toxoplasmosis Histoplasmosis Syphilis Autoimmune disease Systemic lupus erythematosus Sjögren s syndrome Antiphospholipid antibody syndrome Behcet s disease Neurosarcoid Other B12 deficiency Complicated migraine Nonspecific WM lesions SVID MS Mimics on MRI 7

NONSPECIFIC WM LESIONS 32 yo diagnosed with MS in 2006 MRI done for recurrent headache Pain in multiple locations refractory to treatment Cervical and thoracic spine MRI: normal Lumbar puncture No cells, normal protein, no oligoclonal bands Labs for other conditions normal B12, ESR, ANA, SSA/B, ACE level MRI: NONSPECIFIC WM LESIONS 8

MRI: NONSPECIFIC WM LESIONS NEUROMYELITIS OPTICA 30 yo African-American woman with a history of optic neuritis and lupus since 2003 Treated with Avonex and azathioprine Did very well and stopped treatment and no follow-up for years 9

NEUROMYELITIS OPTICA Presented with confusion in 2011 Lumbar puncture done with 5 WBC, no oligoclonal bands Tested positive for NMO antibody Treated with plasmapheresis and monoclonal antibody NEUROMYELITIS OPTICA: BRAIN MRI 10

NEUROMYELITIS OPTICA: 1/12 T-SPINE MRI, 1/13 11

NEUROMYELITIS OPTICA MRI brain variable, often few lesions initially Spinal cord MRI with longitudinally extensive lesion (3 segments) NMO-IgG seropositive status NMOSD may show variability NEUROSARCOID: HISTORY 63 yo woman presents with recent MS diagnosis Symptoms include vertigo, dragging right leg LE pain and fatigue began many years ago MRI suspicious for demyelinating disease Lumbar puncture: many white cells (120), elevated protein, low glucose, and positive oligoclonal bands 12

NEUROSARCOID: MRI NEUROSARCOID: MRI 13

NEUROSARCOID: SPINE MRI NEUROSARCOID: FOLLOW-UP Extensive infectious disease workup was negative Meningeal biopsy normal Diagnosed with neurosarcoid Autoimmune systemic inflammatory condition Lesions may mimic MS Often leads to meningeal enhancement Optic chiasm and nerves often affected May involve spinal cord lesions Patient stable on TNF-alpha blocker Skin lesions 5 years later biopsied with evidence of sarcoid 14

SKIN LESION DIAGNOSIS Headaches and pain without relapses uncommon Typically lumbar puncture shows <50 WBCs Typical pattern of lesions can be seen in MS and in other conditions Continue evaluating for other possibilities when MS diagnosis is uncertain 15

MS Spectrum on MRI RIS: MS ON MRI WITHOUT SYMPTOMS Okuda, et. Al. Neurology 2009;72:800 805 16

RIS: CASE EXAMPLE 16 yo female Identical twin Sister diagnosed with MS after multiple symptoms and MRI with changes consistent with MS Twin in NIH study and MRI done annually Report of minor MRI changes on recent research MRI RIS: MRI 17

ESTABLISHED MS: TYPICAL MRI RISKS FOR AGGRESSIVE DISEASE More relapses in first 2 years Male gender Spinal cord disease Number of T2 lesions at baseline Enhancing lesions on therapy Coret, F et al. Multiple Sclerosis: 16(8) 935 941 18

AGGRESSIVE MS AGGRESSIVE MS 19

Tumefactive MS Lesions larger than 2 cm May have edema, mass effect Enhancement typical 70% with MS at follow-up Median time to next event was 4.9 years Younger patients had more relapsing disease Luchinneti, Brain (2008), 131, 1759^1775 TUMEFACTIVE MS 20

TUMEFACTIVE MS Why MRI matters in treatment Patients taking any interferon MRI done after one year Patients followed for EDSS up to 4 years MRI lesions after one year predict future disability No. of New Lesions Patients with Worsening Disability (%) 0 5% 1 54% 2 73% 3 83% Most lesions are clinically silent. MRI can show whether a medication is working. MRI recommended 6 months after medication change. Prosperini L et al. Eur J Neurol. 2009;16:1202-1209. 21

CASE I: STRAIGHTFORWARD 46 yo male Noted red desaturation 6 years ago Diagnosed 4 years ago after vertigo Started a DMT Full recovery from initial symptoms No further relapses No change on MRI MRI 2009 MRI 2013 22

CASE I: POOR PROGNOSIS? Male Had spinal cord lesions at diagnosis and diagnosed with brainstem syndrome Despite some risk factors, no progression or relapses on first-line therapy CASE II: MORE COMPLICATED 30 yo male Diagnosed after one week of bilateral hand weakness and numbness in his feet with L hermitte s sign History of optic neuritis in the right eye 5 years previously 23

INITIAL MRI AT DIAGNOSIS INITIAL SPINAL CORD MRI 24

TREATMENT HISTORY Started on a DMT but multiple steroid courses in the first year Switched to a second DMT, but MRI 6 months later showed multiple enhancing lesions Switched to another therapy and had good clinical response, but changed medications due to concern about risk TREATMENT HISTORY On his 4 th DMT, he again had breakthrough disease Changed to another medication, and again had significant breakthrough disease Now on his 6 th DMT Recent MRI with additional breakthrough 25

BRAIN MRI ON 5 TH DMT BRAIN MRI ON 5 TH DMT 26

MRI IN MONITORING It is easier to prevent than repair Gd+ lesions predict poor outcome MRI lesions 5-10 times more common than symptoms MRI 6 months after change of therapy to assess effectiveness Consider alternatives if active disease CONCLUDING THOUGHTS MRI is a useful tool in diagnosis There are many non-ms causes of WM lesions MRI can be useful in monitoring MS on treatment New T2 lesions or enhancing lesions indicate disease activity Disease activity predicts poor prognosis over time Initial MRI can help with treatment decisions More aggressive MS may need more aggressive therapy Spinal cord lesions, large lesion volume, and black holes indicate worse prognosis 27

QUESTIONS? 28